Qian-zhi Ni - Publications

ARID1A Stimulates Notch-TLL1 Signaling to Induce Cancer-Associated Fibroblast Activation and Intrahepatic Cholangiocarcinoma Development.

Journal: Cancer research

Published: November 06, 2025

PPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis.

Journal: Journal for immunotherapy of cancer

Published: July 19, 2025

Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: June 05, 2024

Correction to: PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3.

Journal: Oncogene

Published: July 26, 2023

Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.

Journal: Future oncology (London, England)

Published: May 03, 2023

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation.

Journal: BMC cancer

Published: April 04, 2023

XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis.

Journal: The Journal of cell biology

Published: March 03, 2023

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study.

Journal: Therapeutic advances in gastroenterology

Published: December 15, 2022

Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol.

Journal: BMJ open

Published: December 15, 2022

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.

Journal: Frontiers in immunology

Published: November 26, 2022

Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.

Journal: Future oncology (London, England)

Published: August 15, 2022

PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 28, 2022